Fig. 2From: Efficacy and safety of lenvatinib monotreatment and lenvatinib-based combination therapy for patients with unresectable hepatocellular carcinoma: a retrospective, real-world study in ChinaKaplan–Meier analysis of overall survival (A), progression-free survival (B), and time to progression (C) in patients receiving lenvatinib monotreatment and lenvatinib-based combination treatmentBack to article page